Workflow
太龙药业(600222) - 2024 Q2 - 季度业绩预告
TALOPHTALOPH(SH:600222)2024-07-11 09:21

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for the first half of 2024 to be between 25 million and 30 million yuan, indicating a turnaround from a loss in the same period last year[8]. - The net profit excluding non-recurring gains and losses is projected to be between 24 million and 29 million yuan for the same period[8]. - In the previous year, the net profit attributable to shareholders was a loss of 38.33 million yuan, and the net profit excluding non-recurring gains and losses was a loss of 40.43 million yuan[16]. - The total profit for the current period is reported as a loss of 48.39 million yuan[9]. - The earnings per share for the current period is reported as a loss of 0.0677 yuan[10]. Operational Improvements - The company has implemented measures to improve quality and efficiency, resulting in a decrease in period expenses and enhanced operational capabilities[11]. - The company has optimized its product and customer structure in response to market conditions, leading to an increase in gross profit margin[17]. Forecast and Reporting - The company assures that there are no significant uncertainties affecting the accuracy of this earnings forecast[17]. - The financial data provided is preliminary and subject to confirmation in the official half-year report[17]. - The announcement was made on July 12, 2024[18].